The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Modern antipsychotic drugs: a critical overview
Open accessAbstract
Conventional antipsychotic drugs, used for a half century to treat a range of major psychiatric disorders, are being replaced in clinical practice by modern "atypical" antipsychotics, including aripiprazole, clozapine, olanzapine, quetiapine, risperidone and ziprasidone among others. As a class, the newer drugs have been promoted as being broadly clinically superior, but the evidence for this is problematic. In this brief critical overview, we consider the pharmacology, therapeutic effectiveness, tolerability, adverse effects and costs of individual modern agents versus older antipsychotic drugs. Because of typically minor differences between agents in clinical effectiveness and tolerability, and because of growing concerns about potential adverse long-term health consequences of some modern agents, it is reasonable to consider both older and newer drugs for clinical use, and it is important to inform patients of relative benefits, risks and costs of specific choices.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
A meta-analysis of randomized controlled trials: Efficacy of selenium treatment for sepsis
Li, S., Tang, T., Guo, P., Zou, Q., Ao, X., Hu, L., & Tan, L. (2019) · Medicine · doi:10.1097/md.0000000000014733 · Cited by 802
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
Neuropsychopharmacology : The Fifth Generation of Progress
Davis, K. L., Charney, D. S., Coyle, J. T., & Nemeroff, C. B. (2002) · Lippincott Williams & Wilkins eBooks · Cited by 747
Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition
(2007) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.45859 · Cited by 737
Leucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13306-5 · Cited by 725
Correll, C. U., Leucht, S., & Kane, J. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.414 · Cited by 709
Antipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management
Haddad, P. M., & Wieck, A. (2004) · Drugs · doi:10.2165/00003495-200464200-00003 · Cited by 634
Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 631
Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Harvey, P. D., & Keefe, R. S. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.176 · Cited by 620
Csernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605
Gilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., & Jeste, D. V. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.692 · Cited by 603
Antipsychotic-induced weight gain: a review of the literature.
Allison, D. B., & Casey, D. E. (2001) · PubMed · Cited by 595
Myocarditis and cardiomyopathy associated with clozapine
Kilian, J. G., Kerr, K., Lawrence, C., & Celermajer, D. S. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10385-4 · Cited by 544
Bilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538
Leucht, S., Barnes, T. R. E., Kissling, W., Engel, R. R., Correll, C., & Kane, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.7.1209 · Cited by 517
Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death
Haddad, P. M., & Anderson, I. M. (2002) · Drugs · doi:10.2165/00003495-200262110-00006 · Cited by 435
Atypical antipsychotics and weightgain — a systematic review
Taylor, D. M., & McAskill, R. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101006416.x · Cited by 433
Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R. (2002) · BMJ · doi:10.1136/bmj.325.7358.243 · Cited by 421
The effects of antipsychotic therapy on serum lipids: a comprehensive review
Meyer, J. M., & Koro, C. E. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.01.014 · Cited by 407
Gill, S. S., Rochon, P. A., Herrmann, N., Lee, P. E., Sykora, K., Gunraj, N., Normand, S.-L. T., Gurwitz, J. H., Marras, C., Wodchis, W. P., et al. (2005) · BMJ · doi:10.1136/bmj.38330.470486.8f · Cited by 402
The Role of Serotonin in Schizophrenia
Bleich, A., Brown, S.-L., Kahn, R., & van Praag, H. M. (1988) · Schizophrenia Bulletin · doi:10.1093/schbul/14.2.297 · Cited by 371
Wahlbeck, K., Cheine, M., Essali, A., & Adams, C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.990 · Cited by 357
Gelenberg, A. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0101 · Cited by 356
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Schooler, N., Rabinowitz, J., Davidson, M., Emsley, R., Harvey, P. D., Kopala, L., McGorry, P. D., Van Hove, I., Eerdekens, M., Swyzen, W., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.947 · Cited by 348
Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?
Matthysse, S. (1973) · PubMed · Cited by 341
Rosenheck, R. (2003) · JAMA · doi:10.1001/jama.290.20.2693 · Cited by 326
Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Lewine, R. R. J., Yurgelun-Todd, D. A., Gur, R. C., Tohen, M., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.985 · Cited by 314
Effects of Newer Antipsychotics on Extrapyramidal Function
Tarsy, D., Baldessarini, R. J., & Tarazi, F. I. (2002) · CNS Drugs · doi:10.2165/00023210-200216010-00003 · Cited by 313
Prolactin Levels and Adverse Events in Patients Treated with Risperidone
Kleinberg, D. L., Davis, J. M., de Coster, R., Van Baelen, B., & Brecher, M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00011 · Cited by 307
Elevated Frequency of Diabetes Mellitus in Hospitalized Manic-Depressive Patients
Cassidy, F., Ahearn, E., & Carroll, J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1417 · Cited by 299
Suicidal risk during treatment with clozapine: a meta-analysis
Hennen, J., & Baldessarini, R. J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.015 · Cited by 287
An overview of the mechanism of action of clozapine.
Meltzer, H. Y. (1994) · PubMed · Cited by 282
Neuroleptic Malignant Syndrome and Atypical Antipsychotic Drugs
Ananth, J., Parameswaran, S., Gunatilake, S., Burgoyne, K., & Sidhom, T. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0403 · Cited by 273
Beasley, C. M., Dellva, M. A., Tamura, R. N., Morgenstern, H., Glazer, W. M., Ferguson, K., & Tollefson, G. D. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.1.23 · Cited by 241
Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L. S., Kreyenbuhl, J., Revicki, D., & Buchanan, R. W. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.11.1021 · Cited by 234
Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate
Fontaine, K. R., Heo, M., Harrigan, E. P., Shear, C. L., Lakshminarayanan, M., Casey, D. E., & Allison, D. B. (2001) · Psychiatry Research · doi:10.1016/s0165-1781(01)00234-7 · Cited by 230
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone
Green, M. F., Marder, S. R., Glynn, S. M., McGurk, S. R., Wirshing, W. C., Wirshing, D. A., Liberman, R. P., & Mintz, J. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01370-7 · Cited by 202
Mechanism of New Antipsychotic Medications: Occupancy Is Not Just Antagonism
Gründer, G., Carlsson, A., & Wong, D. F. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.10.974 · Cited by 199
Atypical antipsychotics and glucose dysregulation: a systematic review
Jin, H., Meyer, J. M., & Jeste, D. V. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.03.024 · Cited by 195
A systematic review of atypical antipsychotic drugs in schizophrenia
Bagnall, A. M., Jones, L., Ginnelly, L., Lewis, R., Glanville, J., Gilbody, S., Davies, L., Torgerson, D., & Kleijnen, J. (2003) · Health Technology Assessment · doi:10.3310/hta7130 · Cited by 178
Dropout rates in randomised antipsychotic drug trials
Wahlbeck, K., Tuunainen, A., Ahokas, A., & Leucht, S. (2001) · Psychopharmacology · doi:10.1007/s002130100711 · Cited by 167
Schizophrenia and obesity: impact of antipsychotic medications.
Wirshing, D. A. (2004) · PubMed · Cited by 162
A Comparison of Risperidone-Induced Weight Gain Across the Age Span
Safer, D. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000130558.86125.5b · Cited by 152
Management of the Negative Symptoms of Schizophrenia: New Treatment Options
M??ller, H.-J. (2003) · CNS Drugs · doi:10.2165/00023210-200317110-00003 · Cited by 141
Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
Newcomer, J. W. (2004) · PubMed · Cited by 132
Clozapine-Associated Neuroleptic Malignant Syndrome: Two New Cases and a Review of the Literature
Karagianis, J. L., Phillips, L., Hogan, K. P., et al. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18286 · Cited by 132
Antipsychotic-Induced Type 2 Diabetes: Evidence From a Large Health Plan Database
Gianfrancesco, F. D., White, R., Wang, R., & Nasrallah, H. A. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085404.08426.3a · Cited by 123
Brain Dopamine Receptors: A Primer on Their Current Status, Basic and Clinical
Baldessarini, R. J., & Tarazi, F. I. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017200 · Cited by 112
Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target
Remington, G. J. (2003) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0334 · Cited by 110
(2004) · PubMed · Cited by 108
The role of serotonin in schizophrenia
Igbal, N., & van Praag, H. M. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)00027-m · Cited by 102
Newer atypical antipsychotic medication versus clozapine for schizophrenia
Tuunainen, A., & Wahlbeck, K. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000966 · Cited by 84
Addington, D. E., Pantelis, C., Dineen, M., Benattia, I., & Romano, S. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1207 · Cited by 76
Lambert, B. L., Chou, C., Chang, K., Tafesse, E., & Carson, W. H. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1092 · Cited by 76
LESLIE, D. L., & Rosenheck, R. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1534 · Cited by 75
Haloperidol dose for the acute phase of schizophrenia
Donnelly, L., Rathbone, J., & Adams, C. E. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001951.pub2 · Cited by 71
Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine
Wehmeier, P. M., Heiser, P., & Remschmidt, H. (2005) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2004.00616_1.x · Cited by 70
Rosenheck, R. A. (2005) · Psychiatric Services · doi:10.1176/appi.ps.56.1.85 · Cited by 65
Cardiac repolarization : bridging basic and clinical science
Gussak, I. B. (2003) · Humana Press eBooks · Cited by 61
The Causes of Underdiagnosing Akathisia
Hirose, S. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007027 · Cited by 53
Theisen, F., Cichon, S., Linden, A., Martin, M., Remschmidt, H., & Hebebrand, J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.5.816 · Cited by 51
Weight Gain During Treatment of Bipolar I Patients With Olanzapine
Hennen, J. A., Perlis, R. H., Sachs, G. S., Tohen, M. F., & Baldessarini, R. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1214 · Cited by 48
Möller, H. ‐. (2000) · The World Journal of Biological Psychiatry · doi:10.3109/15622970009150593 · Cited by 46
Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia
Barnes, T. R. E., Soares‐Weiser, K., & Bacaltchuk, J. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001946.pub2 · Cited by 35
Haloperidol dose for the acute phase of schizophrenia
Donnelly, L., Waraich, P. S., Adams, C. E., Hamill, K. M., Martí, J. L. P., Figuls, M. R. I., & Rathbone, J. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001951 · Cited by 33
Body Mass Index Increase of 58% Associated With Olanzapine
Bryden, K. E., & Kopala, L. C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1835 · Cited by 30
Ziprasidone: profile on safety
Goodnick, P. J. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.10.1655 · Cited by 30
Clozapine can induce high dopamine D 2 receptor occupancy in vivo
Suhara, T., Okauchi, T., Sudo, Y., Takano, A., Kawabe, K., Maeda, J., & Kapur, S. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0967-0 · Cited by 28
Clozapine-Induced Akathisia in Children with Schizophrenia
Gogtay, N., Sporn, A. L., Alfaro, C. L., Mulqueen, A., & Rapoport, J. L. (2002) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454602762599899 · Cited by 21
Atypical Antipsychotic Medications and the Treatment of Schizophrenia
Lewis, D. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.177 · Cited by 17
Kutcher, S., Brooks, S. J., Gardner, D. M., Honer, B., Kopala, L. C., Labelle, A., Lalonde, P., MALLA, A. K., Milliken, H., Soni, J., et al. (2005) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.1.2.89.61042 · Cited by 15
Self-citationCentral action beta-blockers versus placebo for neuroleptic-induced acute akathisia
Lima, A., Soares-Weiser, K., Bacaltchuck, J., & Barnes, T. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001946 · Cited by 10
QT Interval and Its Drug-Induced Prolongation
Zaręba, W., & Moss, A. J. (2003) · Contemporary cardiology · doi:10.1007/978-1-59259-362-0_14 · Cited by 9
Cited by
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301
Self-citationIncidence, risk factors and consequences of ICU delirium
Ouimet, S., Kavanagh, B. P., Gottfried, S. B., & Skrobik, Y. (2007) · Intensive Care Medicine · doi:10.1007/s00134-006-0399-8 · Cited by 972
The Anxiolytic Effects of Exercise: A Meta-Analysis of Randomized Trials and Dose–Response Analysis
Wipfli, B. M., Rethorst, C. D., & Landers, D. M. (2008) · Journal of Sport and Exercise Psychology · doi:10.1123/jsep.30.4.392 · Cited by 480
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 402
Drug-Induced Urinary Retention: Incidence, Management and Prevention
Verhamme, K. M. C., Sturkenboom, M. C. J. M., Stricker, B. H. C., & Bosch, R. (2008) · Drug Safety · doi:10.2165/00002018-200831050-00002 · Cited by 264
Metadata
- Authors
- Gardner, D. M.
- Venue
- Canadian Medical Association Journal
- Publisher
- CMA Joule Inc.
- Published
- 2005-06-21
- Volume
- 172
- Issue
- 13
- Pages
- 1703-1711
- ISSN
- 0820-3946 (ISSN-L)
- 1488-2329
- OpenAlex
- W2097648013
- Cited by
- 422
- References
- 88
- FWCI
- 21.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.